WO1999053064A3 - Methods of delivering glp-1 - Google Patents

Methods of delivering glp-1 Download PDF

Info

Publication number
WO1999053064A3
WO1999053064A3 PCT/IB1999/000651 IB9900651W WO9953064A3 WO 1999053064 A3 WO1999053064 A3 WO 1999053064A3 IB 9900651 W IB9900651 W IB 9900651W WO 9953064 A3 WO9953064 A3 WO 9953064A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
glp
delivering
delivering glp
mutein
Prior art date
Application number
PCT/IB1999/000651
Other languages
French (fr)
Other versions
WO1999053064A2 (en
Inventor
Bernard Thorens
Original Assignee
Modex Therapeutiques S A
Bernard Thorens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modex Therapeutiques S A, Bernard Thorens filed Critical Modex Therapeutiques S A
Priority to AU30472/99A priority Critical patent/AU3047299A/en
Publication of WO1999053064A2 publication Critical patent/WO1999053064A2/en
Publication of WO1999053064A3 publication Critical patent/WO1999053064A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of delivering GLP-1 or a GLP-1 mutein, preferably the Gly8 mutein, for the treatment of Type II diabetes and obesity, are disclosed.
PCT/IB1999/000651 1998-04-13 1999-04-13 Methods of delivering glp-1 WO1999053064A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30472/99A AU3047299A (en) 1998-04-13 1999-04-13 Methods of delivering glp-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8156298P 1998-04-13 1998-04-13
US60/081,562 1998-04-13

Publications (2)

Publication Number Publication Date
WO1999053064A2 WO1999053064A2 (en) 1999-10-21
WO1999053064A3 true WO1999053064A3 (en) 2000-03-16

Family

ID=22164947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/000651 WO1999053064A2 (en) 1998-04-13 1999-04-13 Methods of delivering glp-1

Country Status (2)

Country Link
AU (1) AU3047299A (en)
WO (1) WO1999053064A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
ES2336575T3 (en) 2005-09-22 2010-04-14 Biocompatibles Uk Limited GLP-1 FUSION POLYPEPTIDES (PEPTIDE-1 SIMILAR TO GLUCAGON) WITH INCREASED RESISTANCE TO PEPTIDASE.
DE602006009631D1 (en) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd Spherical microcapsules containing GLP-1 peptides, their production and their use
EP2163243A1 (en) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
ES2614427T3 (en) 2008-11-07 2017-05-31 The General Hospital Corporation C-terminal fragments of glucagonoid peptide 1 (GLP-1)
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
EP2729157B1 (en) 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
WO1997029180A1 (en) * 1996-02-06 1997-08-14 Eli Lilly And Company Diabetes therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
WO1997029180A1 (en) * 1996-02-06 1997-08-14 Eli Lilly And Company Diabetes therapy

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRAIN RESEARCH, (1998 JAN 1) 779 (1-2) 75-83. *
BURCELIN R ET AL: "Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1999 JUN 18) 875 277-85. REF: 42, XP000867062 *
BURCELIN R ET AL: "Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon - like peptide -1.", METABOLISM: CLINICAL AND EXPERIMENTAL, (1999 FEB) 48 (2) 252-8., XP000867050 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; DONAHEY J C ET AL: "Intraventricular GLP -1 reduces short- but not long-term food intake or body weight in lean and obese rats.", XP002128061, retrieved from STN Database accession no. 1998140938 *
GUTNIAK M K ET AL: "GLP -1 tablet in type 2 diabetes in fasting and postprandial conditions.", DIABETES CARE, (1997 DEC) 20 (12) 1874-9., XP000867051 *
NAUCK M A ET AL: "Glucagon - like peptide 1 ( GLP -1) as a new therapeutic approach for type 2 - diabetes.", EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY AND DIABETES, (1997) 105 (4) 187-95, XP000867274 *
NAUCK M.A. ET AL: "Clucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus", HORMONE AND METABOLIC RESEARCH, (1997), 29/9 (411-416), XP000867277 *

Also Published As

Publication number Publication date
WO1999053064A2 (en) 1999-10-21
AU3047299A (en) 1999-11-01

Similar Documents

Publication Publication Date Title
WO2003018516A3 (en) Glucagon-like peptide-1 analogs
EP1695983A3 (en) Glucagon-like peptide-1 analogs
ZA982187B (en) Adsorbent construction; and, method.
ZA99104B (en) Method for administering ASPB28-human insulin.
ZA987844B (en) Therapeutic combinations.
EP0997151A3 (en) Method for administering insulinotropic peptides
EP0679377A3 (en) Method of correction of the foot, splint for use in practicing the method, and footwear with a splint.
EP0655702A3 (en) Stylus-input recognition correction manager.
AU2263197A (en) Diabetes therapy
HK1022416A1 (en) Wheelchair.
ZA9811466B (en) Glucagon-like peptide-1 crystals.
HK1025746A1 (en) Syringe.
AU6868498A (en) Method, implant, and apparatus for refractive keratoplasty
HK1024848A1 (en) Breathing assistance improvements.
ZA985546B (en) Treatment of insulin resistance.
ZA97976B (en) Uniform drug delivery theraphy.
AU6246199A (en) Human interleukin-b50, therapeutic uses
HUP9900715A3 (en) Therapeutic agent for diabetes, pharmaceuticals contg. them
ZA979573B (en) (Alpha-aminophosphino) peptide derivatives, process for their preparation and their therapeutic applications.
ZA975510B (en) Method for increasing the anti-wettability of a body, body treated in this way and applications thereof.
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
WO1999053064A3 (en) Methods of delivering glp-1
IL129927A0 (en) 1,4-Diazabicyclo (2.2.2) oct-2-ylmethyl derivatives their preparation and therapeutic application
ZA991102B (en) Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery.
ZA959630B (en) Diaminocyclobutene-3, 4-diones.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase